CD38 and Miyoshi myopathy: However, based on the relevant investigations described above, the encapsulation of anti-myeloma drugs (such as doxorubicin) in exosomes as well as the surface modification of exosomes with targeting molecules (such as anti-CD38 mAb, anti-CD138 mAb and anti-SLAMF7 mAb) are very promising strategies for the therapy of MM.